Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Legend Biotech

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
Biotechnology Markets and money
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Analyst Ratings for Legend Biotech

In the past quarter, analysts have shared their diverse perspectives on Legend Biotech (NASDAQ: LEGN), totaling 4 ratings. These recent ratings consist of 1 Bullish, 2 Somewhat Bullish, 1 Indifferent, and no Bearish ratings. There have been no new ratings in the last month, signaling a steady forecast. The average price target for Legend Biotech over the next year is $82.75, with a high estimate of $94.00 and a low estimate of $65.00. This average target has decreased by 11.02% compared to the previous target of $93.00.

Recent Analyst Actions

Leonid Timashev from RBC Capital upholds an Outperform rating with a price target of $85.00.
Gena Wang at Barclays upgraded the rating to Overweight with a price target of $94.00, up from the previous $93.00.
Mitchell Kapoor from HC Wainwright & Co. maintains a Buy rating with a price target of $87.00.
George Farmer at Scotiabank announced a Sector Perform rating with a price target of $65.00.

Analysts adjust their recommendations based on market conditions and company performance, demonstrating changes by maintaining, increasing, or decreasing their position on Legend Biotech.

LEGN Stock Price Analysis: Potential Growth and Volatility on March 7, 2024

On March 7, 2024, LEGN stock closed at $64.22, a $0.44 increase from the previous close, representing a 0.69% rise. LEGN is trading below its 200-day moving average, indicating potential resistance. The recent price increase may signal investor interest. LEGN remained unchanged in after-hours trading, suggesting stability. The stock’s performance on March 7, 2024, indicates volatility and potential growth. Investors should monitor closely for continued positive momentum.

LEGN Stock Shows Promising Performance with Significant Revenue Growth on March 7, 2024

On March 7, 2024, LEGN stock showed promising performance with significant increases in total revenue, net income, and earnings per share. According to data from CNN Money, the company reported a total revenue of $117.00 million for the past year, marking a 70.0% increase compared to the previous year. In the third quarter alone, total revenue reached $96.01 million, showing a 30.93% increase from the previous quarter.

Despite the positive revenue growth, LEGN reported a net income of -$446.35 million for the past year, reflecting a 10.6% decrease compared to the previous year. However, in the third quarter, the company managed to reduce its net loss to -$62.21 million, representing a significant 68.76% increase from the previous quarter.

Earnings per share also saw improvements, with a reported EPS of -$2.81 for the past year, showing a 2.05% increase compared to the previous year. In the third quarter, EPS reached -$0.34, marking a substantial 69.88% increase from the previous quarter.

Overall, LEGN stock demonstrated strong financial performance on March 7, 2024, with notable increases in total revenue, net income, and earnings per share. Investors may view these positive results as a sign of the company’s growth potential and future profitability.

Tags: LEGN
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Retail Stock Bull Market

Analyst Revises Price Target for Foot Locker Based on Market Conditions

Food Producers Stock Exchange

Analysts Bullish on BellRing Brands Strong Buy Recommendations and Positive Outlook

Unlocking Value: The Economic Potential of Iron-Titanium-Vanadium Projects

Westlake Corporation CFO Sells Shares Amid Financial Challenges

Recommended

Kraft Heinz Stock

Is Kraft Heinz’s High Dividend Yield a Value Trap?

2 months ago
Middleby Stock

Middleby Shares Extend Decline Amid Mixed Signals and Lowered Guidance

6 months ago
Confluent Stock

Confluent Strengthens Leadership Team with New CTO Appointment

5 months ago

Vevye The Revolutionary Solution for Dry Eye Disease

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Trending

RBB Stock
Analysis

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

by SiterGedge
February 8, 2026
0

RBB Bancorp concluded its 2025 fiscal year with a notably stronger balance sheet, driven by a substantial...

Cassava Sciences Stock

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

February 8, 2026
DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review
  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com